PSEN1 and Alzheimer disease: Strikingly, fingolimod treatment of APP/PS1 mice decreased astrocyte area back to WT control levels (WT + FTY720: 2.73 ± 0.28, AD + FTY720: 2.71 ± 0.37; Figure 5C, left).